biosyn Arzneimittel

biosyn Arzneimittel GmbH is a German pharmaceutical and biotech company founded in 1984 and headquartered in Fellbach, near Stuttgart. Its core business is trace element therapeutics - most notably high-dose selenium injections - alongside the isolation of glycoproteins from marine sources for oncology medications. Around 70 employees work at the company, roughly 70% of sales are generated outside Germany, and its products are distributed in 27 countries.

The flagship product, selenase®, is a high-dose selenium injection, in which category biosyn is the global market leader. The second strand of the business concerns glycoproteins isolated from Megathura crenulata (the Giant Keyhole Limpet), a marine snail sourced from California and used in oncology drugs. These active ingredients are produced in two GMP-certified facilities - one in Germany and one in the USA - which the company describes as worldwide unique.

Technical work spans pharmaceutical manufacturing, biotechnology, GMP-certified active ingredient production, and research into selenium therapy. biosyn has been initiating and funding medical research for over 30 years, with a focus on the role of selenium in intensive care, oncology, and thyroid disease. Its products are supplied to hospitals, private practice physicians, and naturopathic practitioners across the fields of intensive care medicine, endocrinology, thyroid treatment, and oncology.